Exothera Nucleic Acids launched in partnership with Quantoom Biosciences

Continuous RNA production offered as a service using the Nfinity platform

26 Apr 2023
James Li
Blood Banking Scientist

Exothera, through its partnership with Quantoom Biosciences, will utilise Quantoom’s Nfinity™ technology, to become the first contract development and manufacturing organization to offer an off-the-shelf process for the continuous production of RNA. Exothera will provide this service through a new business unit, Exothera Nucleic Acids, that will focus on accelerating the process development and manufacturing of RNA vaccines and therapeutics. Continuous manufacturing of RNA can provide significant advantages in terms of efficiency, productivity, quality control, cost-effectiveness, and scalability.

Exothera will provide the service through a new business unit, Exothera Nucleic Acids, that focuses on accelerating the process development and manufacturing of RNA vaccines and therapeutics.

Thibault Jonckheere, CEO of Exothera, commented, "The market potential for RNA therapies continues to grow and expand into new therapeutic areas, but the process of developing a new RNA vaccine or therapeutic is hindered by outdated technology that was never intended to scale for commercialization. We are thrilled to not only announce the launch of our new business unit focused on nucleic acids, but also our strategic collaboration with Quantoom Biosciences. This collaboration enables Exothera to make the highest quality RNA for vaccines and therapeutics with low-risk process development and almost guaranteed product quality from sequence up to mass production in a much shorter time than previously possible."

"We're thrilled by this new partnership which marks a new milestone for Quantoom, added José Castillo, CEO of Quantoom. "The advantages of continuous manufacturing for RNA are clear, and we believe this partnership will provide significant benefits to biotech and pharma companies developing RNA vaccines and therapeutics. By combining Exothera's expertise with our cutting-edge platform, we can simplify the process and accelerate timelines for RNA development and production. We're excited to see the impact this partnership will have on the industry and ultimately, on patients' lives."

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags